JR-AB2-011
目录号 : GC34909
JR-AB2-011 是一种通过构效关系（SAR）研究发现的改进型 mTORC2 抑制剂，其半抑制浓度（IC50）为 0.36µM。
Cas No.:2411853-34-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
JR-AB2-011 is an improved mTORC2 inhibitor identified through structure-activity relationship (SAR) studies with an IC50 value of 0.36μM[1-2]. JR-AB2-011 was found to bind Rictor and inhibit its association with mTOR according to further mechanistic investigations[2].
In vitro, treating human chondrocytes with JR-AB2-011(50, 100, or 250µM) inhibited the activity of mTORC2 and prevented the inflammatory, catabolic, and apoptotic responses induced by IL-1β through the modulation of IκB-α/NF-κB activity[3]. Treating leukemia/lymphoma cells with 5µM JR-AB2-011 induced a rapid drop in the cell respiration rate, which was variably compensated by an increased glycolytic rate[4]. In RAW264.7 cells, mTORC2 was inhibited by 1μM JR-AB2-011, and JR-AB2-011 significantly blocked the effects of Dioscin and IL-4, leading to decreased expression of CD206, Arg-1, IL-10, and Ym1, as well as reduced uptake of free fatty acids[5].
In vivo, six-week-old male C57BL/6N mice treated with JR-AB2-011(20mg/kg; intraperitoneally) for 13 days showed a significantly decreased hepatic tumor burden after dissection[6]. Treatment with JR-AB2-011 (4mg/kg; i.p.) in BALB/c nude mice for 10 days significantly reduced tumor size, prolonged the survival of mice bearing X01-Luc (X01 GSC transduced with a luciferase-expressing vector) orthotopic xenograft tumors, and reduced the downstream gene expression involving mTOR2[7]. Rats were administered JR-AB2-011 (1mg/kg; i.p.), which reversed both the Zymosan-induced reduction in mean arterial pressure (MAP) and the increase in heart rate (HR), inhibited the enhanced expression of protein kinase B (Akt), IκB-α, IKKα, NF-κB p65, inducible nitric oxide synthase (iNOS), nitrotyrosine, cyclooxygenase 2 (COX-2), tumor necrosis factor (TNF)-α, and interleukin (IL)-1β[8].
References:
[1] Zhang A, et al. CCL17 exerts neuroprotection through activation of CCR4/mTORC2 axis in microglia after subarachnoid haemorrhage in rats. Stroke Vasc Neurol. 2022 Jul 26;8(1):4–16.
[2] Benavides-Serrato A, Lee J, Holmes B, et al. Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma [retracted in: PLoS One. 2023 Sep 8;18(9):e0291490.]. PLoS One. 2017;12(4):e0176599.
[3] Temiz-Resitoglu M, Sabrie Z, Tiftik RN, et al. mTORC2 inhibition by JR-AB2-011 improves IL-1β-induced inflammation, catabolic response, and apoptosis in human chondrocytes through IκB-α/NF-κB p65. Cell Mol Biol (Noisy-le-grand). 2024;70(9):37-43.
[4] Kořánová T, Dvořáček L, Grebeňová D, Kuželová K. JR-AB2-011 induces fast metabolic changes independent of mTOR complex 2 inhibition in human leukemia cells. Pharmacol Rep. 2024;76(6):1390-1402.
[5] Wu MM, Wang QM, Huang BY, et al. Dioscin ameliorates murine ulcerative colitis by regulating macrophage polarization. Pharmacol Res. 2021;172:105796.
[6] Guenzle J, Akasaka H, Joechle K, et al. Pharmacological Inhibition of mTORC2 Reduces Migration and Metastasis in Melanoma. Int J Mol Sci. 2020;22(1):30.
[7] Zhou S, Lin W, Jin X, et al. CD97 maintains tumorigenicity of glioblastoma stem cells via mTORC2 signaling and is targeted by CAR Th9 cells. Cell Rep Med. 2024;5(12):101844.
[8] Sabrie Z, Temiz-Resitoglu M, Kalkan T, et al. Protection by selective mTORC2 inhibition of Zymosan-induced hypotension and systemic inflammation mediated via IKKα/IκB-α/NF-κB activation. Prostaglandins Other Lipid Mediat. 2024;175:106918.
JR-AB2-011 是一种通过构效关系（SAR）研究发现的改进型 mTORC2 抑制剂，其半抑制浓度（IC50）为 0.36µM[1-2]。进一步的机制研究表明，JR-AB2-011 可以与 Rictor 结合并抑制其与 mTOR 的结合[2]。
在体外，用 JR-AB2-011（50、100 或 250µM）处理人软骨细胞，可以抑制 mTORC2 的活性，并通过调节 IκB-α/NF-κB 活性，防止由白细胞介素-1β（IL-1β）诱导的炎症、分解代谢和凋亡反应[3]。在白血病/淋巴瘤细胞中，使用 5µM 的 JR-AB2-011 处理会导致细胞呼吸速率迅速下降，而细胞通过增加糖酵解速率来不同程度地补偿这一变化[4]。在 RAW264.7 细胞中，1µM 的 JR-AB2-011 可以抑制 mTORC2 的活性，并且显著阻断了 Dioscin 和 IL-4 的作用，导致 CD206、精氨酸酶-1（Arg-1）、IL-10 和 Ym1 的表达降低，以及游离脂肪酸的摄取减少[5]。
在体内，6 周龄的雄性 C57BL/6N 小鼠通过腹腔注射接受 JR-AB2-011（20mg/kg）处理 13 天后，解剖发现肝脏肿瘤负荷显著减少[6]。在 BALB/c 裸鼠中，使用 JR-AB2-011（4mg/kg；腹腔注射）处理 10 天，可以显著缩小肿瘤体积，延长携带 X01-Luc（X01 胶质干细胞系转导荧光素酶表达载体）原位异种移植肿瘤的小鼠的生存期，并降低涉及 mTOR2 的下游基因表达[7]。在大鼠中，通过腹腔注射给予 JR-AB2-011（1mg/kg）可以逆转 Zymosan 诱导的平均动脉压（MAP）降低和心率（HR）增加，抑制蛋白激酶 B（Akt）、IκB-α、IKKα、NF-κB p65、诱导型一氧化氮合酶（iNOS）、硝酪氨酸、环氧化酶 2（COX-2）、肿瘤坏死因子（TNF）-α 和白细胞介素（IL）-1β 的增强表达[8]。
| Cell experiment [1]: | |
Cell lines | human chondrocyte cell line |
Preparation Method | The cell culture was performed in DMEM/F12 containing 10% FBS, 1% penicillin-streptomycin, and L-glutamine at 37°C in 5% CO2 incubator. When cell confluence reached 80%, the subculture was carried out. In 6-well plates, experimental cells were cultured at a density of 2x104 cells per well and grown to 80%-90% confluence. Through the stimulation of cultured chondrocytes with 2ng/mL of recombinant IL-1β for 24 hours, an in vitro osteoarthritis model has been established. IL-1β was used to activate the cells for 24 hours in either the absence or presence of JR-AB2-011(50, 100, or 250µM). JR-AB2-011(50, 100, or 250µM) was administered to chondrocytes simultaneously with IL-1β. Cells were divided into five groups: control; IL-1β (2ng/mL); IL-1β (2ng/mL) + 50µM JR-AB2-011; IL-1β (2ng/mL) + 100µM JR-AB2-011; and IL-1β (2ng/mL) + 250µM JR-AB2-011. All cells were incubated at 37°C in a 95% air, 5% CO2 environment. |
Reaction Conditions | 50, 100, or 250µM; 24h |
Applications | In IL-1β-stimulated chondrocytes, mTORC2 activity was increased with increased phosphorylation of Akt and expression of rictor. IL-1β increased the expression of p-IκBα, p-NF-κB p65, NF-κB p65, IL-6, TNF-α, iNOS, Bax, and caspase3 proteins and decreased the expression of IκB-α. All of these IL-1β-induced alterations were prevented by JR-AB2-011 in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | six-week-old male C57BL/6N mice |
Preparation Method | Six-week-old male C57BL/6N mice (n=20) underwent splenic injection of 2.5x105 B16 melanoma cells containing firefly luciferase-expressing plasmid pCHMWS_Luciferase under isoflurane anesthesia and 200mg/kg metamizole pain treatment. Treatment with 20mg/kg JR-AB2-011 intraperitoneal (i.p.) or solvent control daily for 13 days was started one day after tumor inoculation (n=10). Thirteen days after intrasplenic injection, mice were terminated. |
Dosage form | 20mg/kg; 13 days; intraperitoneal |
Applications | The analysis revealed that animals treated with JR-AB2-011 showed significantly decreased hepatic tumor burden after dissection. In one animal, no hepatic tumor burden was detectable after treatment with JR-AB2-011. |
References: | |
| Cas No. | 2411853-34-2 | SDF | |
| Canonical SMILES | ClC1=C(Cl)C=C(NC(N2/C(SC(C)C2)=N/C3=CC=C(F)C=C3)=O)C=C1 | ||
| 分子式 | C17H14Cl2FN3OS | 分子量 | 398.28 |
| 溶解度 | DMSO : 62.5 mg/mL (156.92 mM);Water : < 0.1 mg/mL (insoluble) | 储存条件 | 4°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5108 mL | 12.554 mL | 25.108 mL |
| 5 mM | 0.5022 mL | 2.5108 mL | 5.0216 mL |
| 10 mM | 0.2511 mL | 1.2554 mL | 2.5108 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet